Massachusetts Financial Services Co. MA Reduces Stock Holdings in Masimo Co. (NASDAQ:MASI)

Massachusetts Financial Services Co. MA trimmed its holdings in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 58.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 721,726 shares of the medical equipment provider's stock after selling 1,000,059 shares during the period. Massachusetts Financial Services Co. MA owned approximately 1.36% of Masimo worth $90,894,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Riverview Trust Co acquired a new position in shares of Masimo in the 1st quarter valued at $25,000. GAMMA Investing LLC lifted its stake in shares of Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 111 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Masimo by 851.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 264 shares during the period. Parallel Advisors LLC lifted its stake in shares of Masimo by 48.3% in the 4th quarter. Parallel Advisors LLC now owns 445 shares of the medical equipment provider's stock valued at $52,000 after purchasing an additional 145 shares during the period. Finally, Lazard Asset Management LLC lifted its stake in shares of Masimo by 5,730.0% in the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider's stock valued at $85,000 after purchasing an additional 573 shares during the period. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MASI. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Wednesday, August 7th. Piper Sandler upped their price objective on shares of Masimo from $160.00 to $165.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Masimo currently has a consensus rating of "Moderate Buy" and an average target price of $144.67.

Masimo Price Performance

Shares of Masimo stock traded down $2.58 during trading hours on Thursday, reaching $111.73. 986,672 shares of the company's stock were exchanged, compared to its average volume of 644,487. Masimo Co. has a 1 year low of $75.22 and a 1 year high of $153.93. The company has a market capitalization of $5.94 billion, a P/E ratio of 77.76 and a beta of 0.98. The business has a fifty day moving average of $114.81 and a two-hundred day moving average of $125.17. The company has a quick ratio of 1.15, a current ratio of 2.09 and a debt-to-equity ratio of 0.55.

Masimo (NASDAQ:MASI - Get Free Report) last released its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.77 by $0.09. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The business had revenue of $496.30 million during the quarter, compared to analyst estimates of $493.92 million. During the same quarter in the prior year, the firm earned $0.62 earnings per share. The company's revenue for the quarter was up 9.0% compared to the same quarter last year. As a group, research analysts predict that Masimo Co. will post 3.87 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.